#USA #Birmingham #Shilpa Medicare #Alveolus Bio #Lung Therapy

Strategic Investment to Advance Lung Therapy Development

Alveolus Bio, an innovative biotech firm focused on respiratory medications, has announced a significant strategic funding round led by Shilpa Medicare. This collaboration is poised to elevate Alveolus Bio's efforts to develop pioneering lung therapies, spearheaded by Dr. Vivek Lal from the University of Alabama in Birmingham.

Shilpa Medicare, a global pharmaceutical leader with extensive experience in respiratory therapeutics and biotechnological advancements, is set to become Alveolus Bio's exclusive global development and manufacturing partner through its biological division, Shilpa Biologics. This partnership aims to propel Alveolus Bio's proprietary platform for living biotherapeutics and small molecules into phase 2 clinical trials and first-in-human studies, with a leading therapy for Chronic Obstructive Pulmonary Disease (COPD) currently making rapid progress.

The expertise of Shilpa Medicare in drug research, development, production, and regulatory knowledge is viewed as a cornerstone for accelerating Alveolus Bio’s clinical initiatives. The strategic commitment not only enhances Alveolus’ clinical development of its respiratory microbiota-based inhaled therapeutics (resMIT) platform but also addresses unmet needs in treating conditions such as COPD, bronchopulmonary dysplasia (BPD), and pulmonary fibrosis.

Gaurav Mehta, CEO of Alveolus Bio, expressed that winning Shilpa as a primary investor marks a pivotal step for their company. He noted, "Their global leadership aligns seamlessly with our vision to redefine lung disease treatment."

Dr. C. Vivek Lal, the founder and Chief Scientific Officer of Alveolus Bio, emphasized the potential of their groundbreaking science to transform respiratory therapeutic care, stating, "Through this strategic partnership with Shilpa, we are merging innovative biotechnological solutions with best-in-class marketing, accelerating the introduction of life-changing therapies to the market."

Vishnukant Bhutada, Managing Director of Shilpa Medicare, highlighted the company's focus on supporting groundbreaking biologics, adding that this partnership enhances their innovation pipeline and solidifies their role as a reliable global partner in biotechnological development.

The investment round remains open, inviting additional strategic investors who share Alveolus Bio’s vision of transforming respiratory medicine.

About Shilpa Medicare

Shilpa Medicare is a global pharmaceutical firm covering all stages of drug development and commercialization, specializing in respiratory therapeutics and biotechnological innovations. For more details, please visit www.vbshilpa.com.

About Alveolus Bio

Alveolus Bio, a member of Biostack Ventures, develops cutting-edge therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs addressing COPD, BPD, pulmonary fibrosis, cystic fibrosis, and other respiratory conditions.